Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Artificial Antigen-presenting Cells
Reports summarize artificial antigen-presenting cells research from Johns Hopkins University, Department of Pathology
May 26th, 2009
New research, 'In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC),' is the subject of a report. According to recent research from the United States, "Adoptive immunotherapy for treatment of cancers and infectious diseases is often hampered by a high degree of variability in the final T cell product and in the limited in vivo function and survival of ex vivo expanded antigen-specific cytotoxic T cells (CTL). This has stimulated interest in development of standardized artificial antigen presenting cells (aAPC) to reliably expand antigen specific CTL." "However, for successful immunotherapy the aAPC...
Source: Cancer Weekly (2009-05-26)
|
